Want to see DNTH full AI Analyst Report?
DNTH Stock Chart & Stats
$93.26
$0.37(1.44%)
At close: 4:00 PM EST
$93.26
$0.37(1.44%)
Day’s Range― - ―
52-Week Range$18.08 - $107.99
Previous CloseN/A
Volume29.07K
Average Volume (3M)1.38M
Market Cap
$5.62B
Enterprise Value$2.79B
Total Cash (Recent Filing)$1.11B
Total Debt (Recent Filing)$1.36M
Price to Earnings (P/E)―
Beta0.90
Next Earnings
Aug 06, 2026EPS Estimate
-0.85Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding54,666,233
10 Day Avg. Volume1,048,269
30 Day Avg. Volume1,375,133
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)3.16
Price to Sales (P/S)764.98
P/FCF Ratio-12.05
Enterprise Value/Market Cap0.50
Enterprise Value/Revenue2.09K
Enterprise Value/Gross Profit2.22K
Enterprise Value/Ebitda-257.10
Forecast
1Y Price Target
$135.29Price Target Upside45.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-3.75
Revenue Forecast (FY)$1.19M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthVery low leverage and rising equity/assets provide durable financial flexibility, supporting multi-year R&D and clinical programs without immediate refinancing pressure. This capacity lowers bankruptcy risk, funds optionality for programs, and sustains operations through development milestones.
Positive Phase 3 Interim DataA 75% responder rate in Phase 3 Part A materially de-risks the lead program and supports an early-go decision, potentially shortening development timelines. This structural clinical progress strengthens competitive positioning and raises the odds of eventual commercial launch.
Governance ContinuityReaffirmation of the board and auditor signals governance stability and investor tolerance for management strategy. Consistent leadership and independent auditing support disciplined clinical execution and reliable financial oversight over the medium term.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow represent a durable funding drain: ongoing trial activity and SG&A sustain high cash outflows. Even with current runway, prolonged programs or slower milestones would pressure liquidity and force strategic tradeoffs or new financings.
Widening Operating LossesMaterial and widening operating losses mean profitability remains distant; high-margin revenue is tiny and overshadowed by R&D and overhead. This structural loss profile requires sustained financing and constrains reinvestment until one or more programs reach commercialization.
Clinical-stage Concentration RiskBeing pre-commercial, the company’s future cash flows and market position hinge on trial outcomes and regulatory approvals. This structural dependency creates binary outcome risk where program failures, delays, or regulatory setbacks can materially impair long-term prospects and require additional capital.
Dianthus Therapeutics News
DNTH FAQ
What was Dianthus Therapeutics, Inc.’s price range in the past 12 months?
Dianthus Therapeutics, Inc. lowest stock price was $18.08 and its highest was $107.99 in the past 12 months.
What is Dianthus Therapeutics, Inc.’s market cap?
Dianthus Therapeutics, Inc.’s market cap is $5.62B.
When is Dianthus Therapeutics, Inc.’s upcoming earnings report date?
Dianthus Therapeutics, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 13 days.
How were Dianthus Therapeutics, Inc.’s earnings last quarter?
Dianthus Therapeutics, Inc. released its earnings results on May 05, 2026. The company reported -$0.85 earnings per share for the quarter, beating the consensus estimate of -$1.072 by $0.222.
Is Dianthus Therapeutics, Inc. overvalued?
According to Wall Street analysts Dianthus Therapeutics, Inc.’s price is currently Undervalued.
Does Dianthus Therapeutics, Inc. pay dividends?
Dianthus Therapeutics, Inc. does not currently pay dividends.
What is Dianthus Therapeutics, Inc.’s EPS estimate?
Dianthus Therapeutics, Inc.’s EPS estimate is -0.85.
How many shares outstanding does Dianthus Therapeutics, Inc. have?
Dianthus Therapeutics, Inc. has 54,666,233 shares outstanding.
What happened to Dianthus Therapeutics, Inc.’s price movement after its last earnings report?
Dianthus Therapeutics, Inc. reported an EPS of -$0.85 in its last earnings report, beating expectations of -$1.072. Following the earnings report the stock price went up 0.199%.
Which hedge fund is a major shareholder of Dianthus Therapeutics, Inc.?
Currently, no hedge funds are holding shares in DNTH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dianthus Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$135.29 (45.06% Upside)
$135.29 (45.06% Upside)
Blogger Sentiment
Bullish
DNTH Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 3.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 3.8%
Last 30 Days ▲ 2.7%
Last 30 Days ▲ 2.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
374.16%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
257.70%
Trailing 12-Months
Company Description
Dianthus Therapeutics, Inc.
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
DNTH Stock 12 Month Forecast
Average Price Target
$135.29
▲(45.06% Upside)
Technical Analysis
Ardelyx
―
Edgewise Therapeutics
―
Janux Therapeutics Inc
―
Amylyx Pharmaceuticals Inc
―
Biohaven Ltd.
―
Ownership Overview
0.13% Insiders
26.12% Mutual Funds
0.59% Other Institutional Investors
60.21% Public Companies and
Individual Investors